Scopus by Title (Ref)
Articles that cite the referenced work, matched by title from the Scopus database.
Comparative efficacy and safety of colistin-based and alternative antibiotic regimens for multidrug-resistant Gram-negative infections: A systematic review and network meta-analysis
International Journal of Infectious Diseases
September 2026
Rayanakorn A.
Open Access
Assessing antibiotic utilization trends and outcomes in patients with carbapenem-resistant Acinetobacter baumannii (CRAB) infections
American Journal of Infection Control
August 2026
Pranjic A.
Indian Society of Critical Care Medicine Guidelines on Evidence-based Recommendations for the Treatment of Carbapenem-resistant Enterobacteriales, Carbapenem-resistant Acinetobacter baumannii, and Carbapenem-resistant Pseudomonas aeruginosa in Critically Ill Patients: A GRADE-guided Approach
Indian Journal of Critical Care Medicine
June 2026
Todi S.K.
Open Access
Sulbactam–Durlobactam for Carbapenem-Resistant Acinetobacter baumannii–calcoaceticus Complex
Pathogens
April 2026
Nappi F.
Open Access
Population Pharmacokinetic Models of Ampicillin–Sulbactam Among Adult Patients with Infectious Diseases: A Systematic Review
Therapeutic Drug Monitoring
February 2026
Poornachandran M.
Carbapenem-Resistant Acinetobacter baumannii: Virulence Factors, Molecular Epidemiology, and Latest Updates in Treatment Options
Microorganisms
September 2025
Karampatakis T.
Open Access
Carbapenem Resistance in Acinetobacter baumannii: Mechanisms, Therapeutics, and Innovations
Microorganisms
July 2025
de Souza J.
Open Access
Sulbactam for carbapenem-resistant Acinetobacter baumannii infections: a literature review
Jac Antimicrobial Resistance
1 April 2025
Spernovasilis N.
Open Access
Fighting resistance with redundancy: a path forward for treating antimicrobial-resistant infections?
Antimicrobial Agents and Chemotherapy
April 2025
Munita J.M.
Open Access
Current and novel therapies for management of Acinetobacter baumannii-associated pneumonia
Critical Reviews in Microbiology
2025
Shein A.M.S.
A retrospective cohort analysis of factors influencing continuous antibiotic therapy with ampicillin
Life Sciences
1 December 2024
Weber L.
Open Access
Optimizing Treatment for Carbapenem-Resistant Acinetobacter baumannii Complex Infections: A Review of Current Evidence
Infection and Chemotherapy
June 2024
Choi S.J.
Open Access
Current treatment options for pneumonia caused by carbapenem-resistant Acinetobacter baumannii
Current Opinion in Infectious Diseases
1 April 2024
Franzone J.P.
All Open Access, Green
Current Therapeutic Approaches for Multidrug-Resistant and Extensively Drug-Resistant Acinetobacter baumannii Infections
Antibiotics
March 2024
Rafailidis P.
Open Access
How to treat severe Acinetobacter baumannii infections
Current Opinion in Infectious Diseases
1 December 2023
Bouza E.
Navigating Available Treatment Options for Carbapenem-Resistant Acinetobacter baumannii-calcoaceticus Complex Infections
Clinical Infectious Diseases
1 May 2023
Shields R.K.
Open Access
The effectiveness of colistin/levofloxacin compared to colistin/meropenem in the treatment of ventilator-associated pneumonia (VAP) caused by carbapenem-resistant Acinetobacter baumannii: a randomized controlled clinical trial
Research in Pharmaceutical Sciences
1 January 2023
Momenzadeh M.
Open Access
Prevalence of polymyxin-induced nephrotoxicity and its predictors in critically ill adult patients: A meta-analysis
World Journal of Clinical Cases
6 November 2022
Wang J.L.
Open Access
European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine)
Clinical Microbiology and Infection
April 2022
Paul M.
Open Access
Treatment of ventilator-associated pneumonia due to carbapenem-resistant Gram-negative bacteria with novel agents: a contemporary, multidisciplinary ESGCIP perspective
Expert Review of Anti Infective Therapy
2022
Giacobbe D.R.
Treatment of patients with serious infections due to carbapenem-resistant Acinetobacter baumannii: How viable are the current options?
Pharmacotherapy
September 2021
O'Donnell J.N.
Treatment of pulmonary infection of extensively drug-resistant acinetobacter baumannii with intravenous colistin sulfate combined with atomization: A case report
Annals of Palliative Medicine
August 2021
Xue X.
Open Access
Systematic review on estimated rates of nephrotoxicity and neurotoxicity in patients treated with polymyxins
Clinical Microbiology and Infection
May 2021
Wagenlehner F.
Open Access
Comparative efficacy and safety of combination therapy with high-dose sulbactam or colistin with additional antibacterial agents for multiple drug-resistant and extensively drug-resistant Acinetobacter baumannii infections: A systematic review and network meta-analysis
Journal of Global Antimicrobial Resistance
March 2021
Liu J.
Open Access